黄芪甲苷防治心肌纤维化研究进展  

Research Progress of Astragaloside IV in the Prevention and Treatment of Myocardial Fibrosis

作　　者：黄倩 蒋虎刚 王新强 严春艳 陈玉林 李雯[1,3] 赵信科 HUANG Qian;JIANG Hugang;WANG Xinqiang;YAN Chunyan;CHEN Yulin;LI Wen;ZHAO Xinke(Gansu University of Chinese Medicine,Lanzhou 730000,Gansu,China;Affiliated Hospital of Gansu University of Chinese Medicine,Lanzhou 730000,Gansu,China;Gansu Provincial Key Laboratory of Chinese Medicine Prevention and Treatment of Chronic Diseases,Lanzhou 730000,Gansu,China)

机构地区：[1]甘肃中医药大学,甘肃兰州730000 [2]甘肃中医药大学附属医院,甘肃兰州730000 [3]甘肃省中医药防治慢性疾病重点实验室,甘肃兰州730000

出　　处：《实用中医内科杂志》2024年第4期37-39,共3页Journal of Practical Traditional Chinese Internal Medicine

基　　金：甘肃省教育科技创新项目-青年博士基金项目(2021QB-080);甘肃省教育科技创新项目教育揭榜挂帅项目(2021jyjbgs-03);甘肃省“双一流”科研重点项目(GSSYLXM-05)。

摘　　要：心肌纤维化(myocardial fibrosis,MF)是指心脏成纤维细胞过度增殖、细胞外基质(extracellular matrix,ECM)过度堆积为主要表现的疾病,是多种心血管疾病发展到一定阶段的共同病理改变,表现为心肌重构及心肌代谢紊乱,最终导致心力衰竭而引发死亡。黄芪甲苷具有抗炎、抗氧化应激、抗细胞凋亡、改善心肌缺血再灌注等药理作用,在心肌纤维化防治方面有着良好的潜力。文章旨在对黄芪甲苷防治心肌纤维化的机制进行综述,为黄芪甲苷临床治疗心肌纤维化提供参考。myocardial fibrosis(MF)is a disease that shows excessive proliferation of cardiac fibroblasts and accumulation of extracellular matrix(ECM).It is a common pathological change in the course of several cardiovascular diseases.The manifesta-tions are myocardial remodeling and myocardial metabolic disorders,which eventually lead to heart failure and death.Astragalo-side IV has pharmacological effects of anti-inflammation,anti-oxidative stress,anti-apoptosis and improvement of myocardial ischemia reperfusion,and has good potential in the prevention and treatment of myocardial fibrosis.This article aims to review the mechanism of astragaloside IV in the prevention and treatment of myocardial fibrosis,and provide reference for the clinical treat-ment of myocardial fibrosis.

关 键 词：黄芪甲苷 心肌纤维化 研究进展 

分 类 号：R285.5[医药卫生—中药学]